 Biocept Inc NASDAQ:BIOC has reported unaudited net revenue of 61.2 million for the financial year ending December 31, 2021. The company also said that it had cash and cash equivalents of about 28 million as of December 31, 2021 as it develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. 